Diligence memo · auto-generated · as of July 2, 2026
Cure Pharmaceutical Holding Corp.
Cure Pharmaceutical Holding Corp. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Cure Pharmaceutical Holding Corp. operates in Pharmaceuticals, based in OXNARD.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Cure Pharmaceutical Holding Corp. has raised $32M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $19M on 2019-05-14.
Most recent recorded round closed around 2020-10-30.
Valuation (modeled)modeled
Provath models Cure Pharmaceutical Holding Corp. at approximately $343M (range $24M–$1.2B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.69× the median modeled value of Series B Pharmaceuticals companies in 2019–2021 (61 peers) — value vs value, same stage and era. Within the normal band (69% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 10 months.
Last raise 5.7 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round was 1.7× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 75% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 76% of those peers.
Closest niche peers: Evolus, Inc., HOOKIPA Pharma Inc., ESSA Pharma Inc., Pieris Pharmaceuticals, Inc., Amylyx Pharmaceuticals, Inc..
Peoplefiled
16 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.